AUTHORS
Sabarish Ayyappan, MD, Wonseog Kim, MD, PhD2, Tae Min Kim, MD, PhD3, Seok-Goo Cho, MD, PhD4, Rafael Andreu, PhD5, Elzbieta Iskierka-Jazdzewska6, Michelle Poon, MD7, H. Miles Prince, MD8, Junning Cao, MD9, Benoit Tessoulin, MD, PhD10, Sung Yong Oh, MD11, Francesca Lorraine Wei Inng Lim12, Cecilia Carpio Segura, MD13, Tran-Der Tan, MD14, Antonio Gutierrez, MD15, Jingxian Cai16, Amulya Uppala, PharmD17, Hesham Mohamed, MD18, Manjusha Namuduri, MD, MHA19, Jurriaan Brouwer-Visser20, David Tucker, MBBS, BSc, DPhil, FRCPath21
AFFILIATIONS
1 City of Hope Cancer Center Atlanta, Newnan Georgia, Georgia, United States
2 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Rep. of South
3 Seoul National University Hospital, Seoul, Korea, Rep. of South
4 The Catholic University of Korea, Seoul, Korea, Rep. of South
5 Hospital Universitari i Politècnic La Fe, Valencia, Spain
6 Copernicus Memorial Hospital, Medical University of Lódz, Lódz, Poland
7 National University Cancer Institute, National University Hospital, Singapore, Singapore
8 Epworth HealthCare and University of Melbourne, Melbourne, Victoria, Australia
9 Fudan University Shanghai Cancer Center, Shanghai, China
10 Nantes University Hospital, Nantes, France
11 Dong-A University Hospital, Busan, Korea, Rep. of South
12 Singapore General Hospital, Singapore, Singapore
13 Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Autonomous University of Barcelona (UAB), Barcelona, Spain
14 Koo Foundation Sun Yat Sen Cancer Center, Taipei City, Taiwan
15 Hospital Universitario Son Espases, IdISBa, Palma, Spain
16 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
17 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
18 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
19 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
20 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
21 Royal Cornwall Hospital, Cornwall, United Kingdom
ABSTRACT
Introduction
In the primary analysis of the Phase 2 ELM-2 study (NCT03888105), odronextamab, a CD20×CD3 bispecific antibody, was associated with encouraging efficacy and a generally manageable safety profile in pretreated patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; Kim WS, et al. Nat Cancer 2025). Here, we report longer-term efficacy and safety outcomes from the R/R DLBCL cohort in ELM-2 with up to 4 years’ follow-up.
Methods
The ELM-2 study design has been previously reported (Kim WS, et al. Nat Cancer 2025). Intravenous odronextamab monotherapy was administered in 21-day cycles, with optimized 0.7/4/20 mg step-up dosing in Cycle (C) 1 to help mitigate the risk of cytokine release syndrome (CRS), followed by 160 mg weekly in C2–4, then maintenance 320 mg once every 2 weeks (Q2W) until disease progression or unacceptable toxicity. Pts with a CR for ≥9 months switched from 320 mg Q2W to once every 4 weeks (Q4W). Pts with the opportunity for response assessment at 12 weeks were included in efficacy analyses. The primary endpoint was objective response rate (ORR) per Lugano criteria, as assessed by independent central review (ICR). Key secondary endpoints included CR rate, duration of response (DOR), duration of CR (DOCR), progression-free survival (PFS) by ICR, overall survival (OS), and safety. Biomarkers were an exploratory endpoint.
Results
At data cut-off (January 21, 2026), 159 pts with R/R DLBCL and ECOG PS 0–1 were enrolled. Median duration of odronextamab exposure was 18.9 weeks (range 0.9–192.1), and median follow-up was 51.3 months (95% confidence interval [CI] 33.4–60.7). Median age was 67 years; 59.1% of pts were male; median number of prior lines of therapy was 2; 76.7% of pts had Ann Arbor score of III–IV; 19.5% had bulky disease; 53.5% had an IPI score of 3–5; 20.8% had transformed DLBCL; 84.9% were refractory at study entry; and 45.9% had activated B-cell–like (ABC) DLBCL. Of 92 pts with available baseline samples, mutations were detected in EZB (26.1%) and TP53 (17.4%). In the 18 (14.2%) patients who switched to Q4W dosing, the median duration of follow-up from the time of switching was 38.5 months (95% CI 26.5–46.8).
In the 127 pts with the opportunity for response assessment at 12 weeks, ORR was 52.0%, CR rate was 32.3%, median DOR was 10.5 months, and median DOCR was 17.0 months. Responses were maintained in high-risk subgroups, such as ABC DLBCL (ORR, 55.4%; CR, 37.5%) and aged ≥75 years (ORR, 50.0%; CR, 46.7%). Median PFS was 4.4 months (95% CI 3.6–5.9) and median OS was 9.2 months (95% CI 6.5–12.7). Pts who switched to Q4W dosing had a median DOR of 23.1 months.
Treatment-emergent adverse events (TEAEs) occurred in 158 pts (99.4%); Grade ≥3 TEAEs were reported in 138 pts (86.8%). Discontinuation due to TEAEs occurred in 28 (17.6%) pts, and 27 (17.0%) pts died due to TEAEs. The most common TEAEs were CRS (57.2%), anemia (42.1%), and pyrexia (39.6%). In the 92 pts who received the optimized 0.7/4/20 mg step-up regimen, CRS was reported in 56.5% of patients (Grade 1, 41.3%; Grade 2, 14.1%; Grade 3, 1.1%). No ICANS events were reported. In the overall cohort, infections occurred in 67.9% of pts (Grade ≥3 41.5%), with pneumonia (19.5%) and COVID-19 (16.4%) being the most common. Circulating tumor DNA (ctDNA) was detected in all 85 pts with available samples at baseline; ctDNA was detected in 50 pts (17 [34.0%] had CR) and not detected in 27 pts (16 [59.3%] had CR) at Week 12; 8 pts did not have available samples at Week 12.
Conclusions
With up to 4 years’ follow-up, odronextamab continues to show clinically meaningful responses in pts with R/R DLBCL from the ELM-2 study, with durable disease control in those who reach a CR. Pts who switched to Q4W dosing maintained durable responses, supporting less frequent maintenance dosing. The safety profile of odronextamab remained manageable with no new safety signals compared with the primary analysis, and no new ICANS or Grade ≥3 CRS events reported during 4 years’ follow-up. These results support investigation of odronextamab in combination with chemotherapy as first-line treatment in pts with untreated DLBCL in the OLYMPIA-3 study (NCT06091865).
DISCLOSURES
Sabarish Ayyappan, MD: Genmab - Honoraria; Beigene - Honoraria; Iowa Oncology Society - Honoraria; Regeneron Pharmaceuticals, Inc. - Honoraria; Incyte - Honoraria; Genentech - Honoraria; BeOne - Honoraria; AstraZeneca - Honoraria; Fate Therapeutics - Honoraria; Peereview - Honoraria; AbbVie - Honoraria; ADC Therapeutics - Honoraria; Seattle Genetics - Honoraria; AstraZeneca - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); Acrotech - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Seattle Genetics - Consultancy (Includes expert testimony)